UNSPSC 85812111: Introduction of oxazolidinones into eye, percutaneous approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of oxazolidinones into eye, percutaneous approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0C328

UNSPSC 85812111, Introduction of oxazolidinones into eye, percutaneous approach (Commodity), shows no recent state and local procurement activity aligned with its nominal clinical scope. The code's narrow focus on a specific pharmaceutical intervention method does not match the diverse health services solicitations posted under this code identifier during the October 2026 period.

Recent opportunities tagged to this code instead cover telehealth urgent care, occupational health screenings, PACE operations, cancer registry and retinal screening services, EMS staffing and billing, wellness programs, medical director roles, and behavioral health initiatives—a portfolio bearing no relationship to ophthalmic pharmaceutical administration. The issuing bodies span state health departments (Nevada Health Authority, Texas HHSC, Colorado Department of Human Services), counties (DeKalb, Forsyth, Sarasota, Seminole, Jackson, Ventura, Rockland, Santa Clara), cities (Atlanta, Ocala, Phoenix), and regional systems (Inland Empire Health Plan, San Mateo Medical Center). Geographic representation includes California, Georgia, Nevada, Colorado, Texas, Arizona, Florida, New York, Illinois, Oregon, and Washington state. The Nevada Health Authority has issued at least two recent opportunities—PACE operations due December 10, 2026 (RFP 41NHA-S4038) and a Rural Value Acceleration Network vendor role due November 30, 2026 (RFP 41NHA-S4031)—suggesting active health services procurement at that agency. The code's use as a catch-all tag for unrelated clinical services indicates either metadata misalignment in the underlying procurement system or a cataloging error by one or more issuing bodies. No vendor should treat this code as indicative of actual market opportunity for oxazolidinone delivery; the activity beneath it reflects general health and behavioral services contracting, not pharmaceutical ophthalmology.